DBV Technologies SA – (NASDAQ:DBVT) was the recipient of unusually large options trading on Tuesday. Stock investors purchased 354 put options on the stock. This is an increase of approximately 608% compared to the typical volume of 50 put options.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC increased its holdings in shares of DBV Technologies by 3,604.2% in the fourth quarter. Perceptive Advisors LLC now owns 978,619 shares of the company’s stock worth $24,075,000 after buying an additional 952,200 shares during the period. ArrowMark Colorado Holdings LLC increased its holdings in shares of DBV Technologies by 94.9% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,007,684 shares of the company’s stock worth $49,389,000 after buying an additional 977,491 shares during the period. University of Notre Dame DU Lac increased its holdings in shares of DBV Technologies by 94.3% in the fourth quarter. University of Notre Dame DU Lac now owns 115,115 shares of the company’s stock worth $2,832,000 after buying an additional 55,860 shares during the period. Sectoral Asset Management Inc increased its holdings in shares of DBV Technologies by 14.2% in the fourth quarter. Sectoral Asset Management Inc now owns 60,298 shares of the company’s stock worth $1,483,000 after buying an additional 7,499 shares during the period. Finally, Emory University increased its holdings in shares of DBV Technologies by 113.4% in the fourth quarter. Emory University now owns 81,916 shares of the company’s stock worth $2,015,000 after buying an additional 43,535 shares during the period. Hedge funds and other institutional investors own 46.36% of the company’s stock.
Shares of DBV Technologies (NASDAQ DBVT) traded up $5.37 during mid-day trading on Wednesday, reaching $26.23. The company’s stock had a trading volume of 3,517,870 shares, compared to its average volume of 292,696. DBV Technologies has a 52-week low of $20.08 and a 52-week high of $50.57.
WARNING: “DBV Technologies Sees Unusually High Options Volume (DBVT)” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.themarketsdaily.com/2018/02/15/dbv-technologies-sees-unusually-high-options-volume-dbvt.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.